Skip to main content

Table 2 PIDs and risk of progression to severe COVID-19 (modified from: http://www.ukpin.org.uk/news-item/2020/03/24/covid-19-uk-pinupdate) [68]

From: Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

Risk Category PID examples and/or molecular defect
Higha IFN-1 pathway defects
PID with production of anti-IFN antibodies
Combined PID
Isolate/PID related CD4 lymphopenia (< 200/mmc)
PID with deregulatory phenotype
PID with anti-inflammatory phenotype uncontrolled by therapyb
Any PID [dependent on intra-venous immunoglobulin (IVIG) substitution therapy or antibiotic prophylaxis] associated to organ damage and/or chronic infection and/or malignancy
Any PID [dependent on intra-venous immunoglobulin substitution therapy or antibiotic prophylaxis] on chronic oral corticosteroid or other immunosuppressant therapy
Any PID which has undergone bone marrow transplant in the last 12 months
Trisomy 21
TLR3, UNC93B1
STAT1, STAT2
APS1/APECED
FHL, XIAP, RAB27A
DIRA
Intermediate XLA, CVI excluded from high risk PID
Chronic Granulomatous Disease (CGD)
Complement deficits
 
Low Minor antibodies deficiencies
Minor complement deficiencies
C1-inhibitor deficiency
IgA deficiency (selected cases)
MBL deficiency, hereditary angioedema
  1. aExamples of PID with at least one report of severe evolution in absence of significative comorbidities
  2. bindirect evidence